Harvard University is playing a key role in uncovering new knowledge about SARS-CoV-2, the causative agent of COVID-19.

Research on novel infectious agents such as this one warrant careful attention to biosafety measures with an understanding that many characteristics of this virus have yet to be elucidated. Any laboratory research related to SARS-CoV-2/COVID-19 should be discussed with your Biosafety Officer prior to initiation.

Much of this research will fall under the scope of the Committee on Microbiological Safety (COMS) and require committee review prior to initiation. Please review the types of experiments and materials that are subject to COMS review or ask your Biosafety Officer to help you make this determination.

Because not all methods of inactivation have yet to be validated for this virus, any receipt of inactivated SARS-CoV-2 samples must be reviewed by your Biosafety Officer.

For more information about the review requirements and biosafety levels assigned to various types of SARS-CoV-2 research, please review the COVID-19/SARS-CoV-2 Laboratory Research: Biosafety Matrix or reach out to your Biosafety Officer.

If your lab will be in possession of or utilize nucleic acids that encode for any portion of the SARS-CoV-2 genome, you must complete the SARS-CoV-2 Nucleic Acid Use Survey.